Feedback / Questions
etrolizumab (RG7413) - Roche
Etrolizumab: Final data from P3 BERGAMOT trial (NCT02394028) for moderate-to-severe Crohn's disease in 2021
(Roche)
-
Sep 15, 2020 -
Roche Pharma Day 2020
P3 data
•
Crohn's disease • Inflammatory Bowel Disease
https://www.roche.com/dam/jcr:7f4a9ab6-60e2-4a69-98f1-1794916cc91d/en/irp20200914-immunology-ophthalmology-infectious-disease.pdf
Sep 15, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious